US 11,717,569 B2
Tolerogenic synthetic nanocarriers
Christopher Fraser, Arlington, MA (US); Grayson B. Lipford, Watertown, MA (US); Christopher J. Roy, Newton, MA (US); and Roberto A. Maldonado, Jamaica Plain, MA (US)
Assigned to Selecta Biosciences, Inc., Watertown, MA (US)
Filed by Selecta Biosciences, Inc., Watertown, MA (US)
Filed on Feb. 22, 2016, as Appl. No. 15/50,397.
Application 15/050,397 is a division of application No. 13/458,021, filed on Apr. 27, 2012, granted, now 9,265,815.
Claims priority of provisional application 61/480,946, filed on Apr. 29, 2011.
Claims priority of provisional application 61/513,514, filed on Jul. 29, 2011.
Claims priority of provisional application 61/531,147, filed on Sep. 6, 2011.
Claims priority of provisional application 61/531,153, filed on Sep. 6, 2011.
Claims priority of provisional application 61/531,164, filed on Sep. 6, 2011.
Claims priority of provisional application 61/531,168, filed on Sep. 6, 2011.
Claims priority of provisional application 61/531,175, filed on Sep. 6, 2011.
Claims priority of provisional application 61/531,180, filed on Sep. 6, 2011.
Claims priority of provisional application 61/531,194, filed on Sep. 6, 2011.
Claims priority of provisional application 61/531,204, filed on Sep. 6, 2011.
Claims priority of provisional application 61/531,209, filed on Sep. 6, 2011.
Claims priority of provisional application 61/531,215, filed on Sep. 6, 2011.
Prior Publication US 2016/0243253 A1, Aug. 25, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/385 (2006.01); A61K 39/35 (2006.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01); A61K 9/127 (2006.01); A61K 9/51 (2006.01); A61K 38/38 (2006.01); A61K 47/50 (2017.01); A61K 47/52 (2017.01); A61K 47/54 (2017.01); A61K 47/59 (2017.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); B82Y 5/00 (2011.01); A61K 39/36 (2006.01); A61K 31/192 (2006.01); A61K 9/14 (2006.01); A61K 38/13 (2006.01); A61K 38/18 (2006.01); B82Y 40/00 (2011.01)
CPC A61K 39/385 (2013.01) [A61K 9/127 (2013.01); A61K 9/14 (2013.01); A61K 9/51 (2013.01); A61K 9/5115 (2013.01); A61K 9/5146 (2013.01); A61K 9/5153 (2013.01); A61K 31/192 (2013.01); A61K 38/13 (2013.01); A61K 38/1816 (2013.01); A61K 38/38 (2013.01); A61K 39/00 (2013.01); A61K 39/001 (2013.01); A61K 39/0008 (2013.01); A61K 39/35 (2013.01); A61K 39/36 (2013.01); A61K 47/50 (2017.08); A61K 47/52 (2017.08); A61K 47/544 (2017.08); A61K 47/593 (2017.08); A61K 47/643 (2017.08); A61K 47/69 (2017.08); A61K 47/6923 (2017.08); A61K 47/6929 (2017.08); A61K 47/6937 (2017.08); B82Y 5/00 (2013.01); G01N 33/505 (2013.01); G01N 33/56972 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/577 (2013.01); B82Y 40/00 (2013.01); G01N 2333/7051 (2013.01); G01N 2333/70514 (2013.01); G01N 2333/70517 (2013.01); Y02A 50/30 (2018.01)] 19 Claims
 
1. A method comprising administering to a subject:
i) a composition comprising a first population of polymeric synthetic nanocarriers coupled to an immunosuppressant wherein the immunosuppressant is rapamycin or a rapamycin analog, and
ii) an APC presentable antigen,
wherein the load of immunosuppressant on average across the first population of polymeric synthetic nanocarriers is at least 2% but no more than 25% (weight/weight), and wherein at least 75% of the polymeric synthetic nanocarriers of the first population have a minimum dimension, obtained using dynamic light scattering, that is greater than 110 nm and a maximum dimension, obtained using dynamic light scattering, that is equal to or less than 500 nm, wherein the subject is in need of antigen-specific tolerance.